Sophiris Bio (SPHS) Given a $6.00 Price Target by HC Wainwright Analysts

Sophiris Bio (NASDAQ:SPHS) received a $6.00 target price from equities research analysts at HC Wainwright in a report released on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 183.02% from the company’s current price.

Other equities research analysts have also recently issued research reports about the stock. Maxim Group set a $6.00 target price on shares of Sophiris Bio and gave the stock a “buy” rating in a research note on Monday, December 11th. ValuEngine upgraded shares of Sophiris Bio from a “strong sell” rating to a “sell” rating in a research note on Friday, December 15th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $6.00.

How to Become a New Pot Stock Millionaire

Shares of Sophiris Bio stock opened at $2.12 on Thursday. Sophiris Bio has a one year low of $1.80 and a one year high of $2.95. The company has a debt-to-equity ratio of 0.84, a current ratio of 9.94 and a quick ratio of 13.37.

Sophiris Bio (NASDAQ:SPHS) last released its earnings results on Wednesday, March 21st. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02).

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Sophiris Bio by 1.0% during the 2nd quarter. Vanguard Group Inc. now owns 731,437 shares of the biopharmaceutical company’s stock worth $1,609,000 after acquiring an additional 7,600 shares during the period. Virtu Financial LLC raised its stake in Sophiris Bio by 389.7% during the 4th quarter. Virtu Financial LLC now owns 169,790 shares of the biopharmaceutical company’s stock worth $385,000 after acquiring an additional 135,119 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Sophiris Bio during the fourth quarter valued at approximately $312,000. Finally, Millennium Management LLC bought a new stake in shares of Sophiris Bio during the fourth quarter valued at approximately $453,000. Institutional investors own 6.37% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3296380/sophiris-bio-sphs-given-a-6-00-price-target-by-hc-wainwright-analysts.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Costco Wholesale  vs. Its Rivals Head to Head Comparison
Costco Wholesale vs. Its Rivals Head to Head Comparison
EZCorp.  Given Consensus Recommendation of “Buy” by Analysts
EZCorp. Given Consensus Recommendation of “Buy” by Analysts
Uniti Group Inc.  Expected to Announce Earnings of $0.63 Per Share
Uniti Group Inc. Expected to Announce Earnings of $0.63 Per Share
WageWorks  Cut to “Hold” at Zacks Investment Research
WageWorks Cut to “Hold” at Zacks Investment Research
Onix  Price Hits $0.0115 on Exchanges
Onix Price Hits $0.0115 on Exchanges
SuperCoin Hits Market Cap of $383,530.00
SuperCoin Hits Market Cap of $383,530.00


© 2006-2018 Ticker Report. Google+.